One study describes the use of biweekly injections of VEGF inhibitor Bevacizumab for one year; this led to a reduction in cyst volume and white matter changes, with a corresponding reduction in bradykinesia, with a plateau at 6 months (ref Fay, 2017). The gene discussed is VEGFA; the disease is cyst.